Company news
Claritas Pharmaceuticals Inc. (OTC:CLAZF) news
Claritas Pharmaceuticals Inc. news releases on 6ix. Latest, Mar 6, 2019: Kalytera Announces Initiation of Study KAL-07 – Food Effect Study
Press releases — page 2
Kalytera Announces Initiation of Study KAL-07 – Food Effect Study
March 6, 2019
Kalytera Announces Private Placement of Convertible Debenture Units
March 5, 2019
Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group
February 26, 2019
Kalytera Reports Additional Positive Data for CBD in Prevention of Acute GVHD
February 5, 2019
KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview
February 1, 2019
Kalytera Announces Change to Scope of Services under Payments Agreements with Salzman Group and Next Share Issuance
January 31, 2019
Kalytera Announces Grant of Stock Options to Certain Directors and Employees
January 28, 2019
Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants
January 22, 2019
Kalytera Announces Initiation of Research Coverage by Echelon Wealth Partners
January 15, 2019
Kalytera Announces Share Issuance and Extension to March 1 under Payments Agreements with Salzman Group
January 14, 2019
Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants
January 11, 2019
Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD
December 20, 2018
Kalytera Announces Additional Share Issuance for Services under Payments Agreement with Salzman Group
December 4, 2018
Kalytera Reports Third Quarter 2018 Financial Results
November 30, 2018
The Future of CBD for Pain Treatment and Sports Medicine: Orion Nutraceuticals Inc. (CSE: ORI), Aurora Cannabis Inc., CannTrust Holdings Inc., Kalytera Therapeutics
November 20, 2018
Kalytera Announces Next Share Issuance for Services under Payments Agreement with Salzman Group
November 12, 2018
Kalytera Announces Next Share Issuance under Payments Agreements with Salzman Group
September 28, 2018
Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
September 27, 2018
Kalytera Announces Grant of Stock Options to Directors and Employees
September 24, 2018
Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD
September 20, 2018
Kalytera Confirms No Material Change in Operations
September 13, 2018
Kalytera Announces Next Payment of Invoices in Shares under Payments Agreements with Salzman Group
September 7, 2018
Kalytera Reports Second Quarter 2018 Financial Results
August 30, 2018
Kalytera Provides Update on Arrangement with Former Shareholders of Talent Biotechs
August 24, 2018
Kalytera Announces Further Payments in Shares under Payments Agreements with Salzman Group
August 17, 2018
Kalytera Therapeutics, Inc. Announces Exercise of Over-Allotment Option
August 16, 2018
Kalytera Completes Pre-IND Meeting with FDA
August 2, 2018
Kalytera Therapeutics Announces Adjournment of 2018 Annual and Special Meeting
July 27, 2018
Kalytera Therapeutics Announces Filing of Amended and Restated Short Form Prospectus
July 26, 2018
Kalytera and Former Shareholders of Talent Biotechs Agree to Deferment of Milestone Payments
July 20, 2018
Kalytera to Enter Medical Cannabis Market With Focus on Treatment of Psoriasis and Menstrual Cramps
July 19, 2018
Kalytera Announces Pre-IND Meeting Date with FDA
July 5, 2018
Kalytera Announces Appointment of Victoria Rudman as Interim Chief Financial Officer and Additional Payments in Shares under Payments Agreements with Salzman Group
June 29, 2018
Kalytera Provides Update on its Lead Program in Prevention and Treatment of GVHD
June 21, 2018
Kalytera Announces Second Payments Agreement with The Salzman Group of Israel
June 18, 2018
Kalytera Announces Next Monthly Payment in Shares under Services Agreement with Salzman Group
June 4, 2018
Kalytera Reports First Quarter 2018 Financial Results
May 30, 2018
Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
May 15, 2018
Kalytera Announces Issuance of Second Patent Covering the Use of CBD in Graft Versus Host Disease
May 2, 2018
Kalytera Reports 2017 Financial Results
May 1, 2018
Kalytera Issues CEO Letter to Shareholders
April 26, 2018
Kalytera Announces Next Payment in Shares under Services Agreement with Salzman Group
April 20, 2018
Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease
April 19, 2018
Kalytera Terminates Pre-Clinical Programs in Bone Disease
April 13, 2018
Kalytera Retains Colwell Capital to Provide Investor Relations Services
April 10, 2018
Kalytera Announces Next Issuance of Shares under Services Agreement with Salzman Group
March 22, 2018
Kalytera Initiates Program to Develop a Novel Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
March 20, 2018
Kalytera Announces Grant of Stock Options to Chief Scientific Officer and Chief Medical Officer
March 14, 2018
Kalytera Announces Further Issuance of Shares under Services Agreement with Salzman Group
February 23, 2018
Kalytera Announces Grant of Stock Options
January 31, 2018